US EditionPrecision Biologics to Present Recent Data on a New Antibody-Drug Conjugate (ADC) Utilizing the Monoclonal Antibody (mAb) PB-223, at AACR Annual Meeting 2025
Summary by CNHI News
11 Articles
11 Articles
All
Left
1
Center
1
Right
Sweetwater Reporter+10 Reposted by 10 other sources
Precision Biologics to Present Recent Data on a New Antibody-Drug Conjugate (ADC) Utilizing the Monoclonal Antibody (mAb) PB-223, at AACR Annual Meeting 2025
BETHESDA, Md., April 25, 2025 /PRNewswire/ -- Precision Biologics, Inc. reports preclinical development and characterization of a novel ADC using its anti-core 2 O-glycans anti-human carcinoma mAb PB-223 will be presented in a poster at the American Association for Cancer…
·Sweetwater, United States
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
